Vedere Bio II, Inc.® is a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death.

Atlas Venture

Samsara BioCapital

Mission BioCapital

Casdin Capital

Octagon Capital Advisors

Retinal Degeneration Fund

Foundation Fighting Blindness

Vedere Bio II

Domain Not Resolving

IPv6

Cloudflare Hosting

Cloudflare DNS

Apache Traffic Server

Chief Financial Officer

Gina Consylman

Chief Operating Officer

Mark Gaffney

SVP Strategy & Program Leadership

Martina Schinke

Director of Finance

Brendan Nicholas

Associate Director, Human Resources and Communications

Ellen Zyrkowski

Director, Synthetic Molecule CMC

Melissa Varner

Senior Manager, Analytical Development

Rachael Ahern

Principal Research Associate/Engineer, Upstream Process Development

Chris Brown

Chief Scientific Officer

Gabor Veres

Board Member

Steve Tregay

Anna-Maria Demetriades

Chief Medical Officer

United States Acquired Companies With Fewer Than 100 Employees (Top 10K)

East Coast Acquired Companies With Fewer Than 1000 Employees (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

East Coast Companies With Less Than $50M in Revenue (Top 10K)

Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.

Series A - Vedere Bio ll

Computer and Software Services and Scientific Services

Cambridge

Massachusetts

United States

North America

Vedere Bio ll

Vedere Bio II Closes Doors After Preclinical Studies Fall Short

Vedere Bio II Announces Appointment of Industry Veteran Gina Consylman as Chief Financial Officer

BioMarin's gene therapy lead jumps ship to rival biotech Vedere Bio II

New spinout of Novartis-acquired startup announces $77M funding

Novartis sees the light, acquiring Vedere for $280M

India

Asia

A multinational pharmaceutical company with a focus on next-generation gene therapy, including AAVs, CAR-Ts, and CRISPR.

Novartis

A biotechnology company specializing in gene therapy and related treatments.

BioMarin

Novartis is a global healthcare company that focuses on developing and providing innovative treatments and therapies for various medical conditions.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 5, 2024 11:10 AM	e7a04d3f
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 11:10 AM	3d35f75e
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	99708e22
crunchbase profile	general	Nov 22, 2024 9:30 AM	cd9862f5
li profile	general	Mar 5, 2024 11:10 AM	00a29028
translate crunchbase fundingrounds	general	Nov 22, 2024 2:02 PM	9f1d3445
peers	general
news basic	general	Mar 5, 2024 11:10 AM	eab14947
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:VEDEREBIO

Novartis